Aurora Cannabis (ACB) Resumen de Acciones
Aurora Cannabis Inc., junto con sus filiales, se dedica a la producción, distribución y venta de cannabis y productos derivados en Canadá y a escala internacional. Saber más
| Puntuación del snowflake | |
|---|---|
| Valoración | 4/6 |
| Crecimiento futuro | 4/6 |
| Rendimiento pasado | 0/6 |
| Salud financiera | 5/6 |
| Dividendos | 0/6 |
Recompensas
Análisis de riesgos
No se han detectado riesgos en ACB a partir de nuestros controles de riesgos.
ACB Community Fair Values
Create NarrativeSee what 53 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Competidores de Aurora Cannabis Inc.
Historial de precios y rendimiento
| Precios históricos de las acciones | |
|---|---|
| Precio actual de la acción | CA$4.22 |
| Máximo en las últimas 52 semanas | CA$9.33 |
| Mínimo de 52 semanas | CA$3.77 |
| Beta | 1.34 |
| Cambio en 1 mes | -11.53% |
| Variación en 3 meses | -6.43% |
| Cambio de 1 año | -24.51% |
| Variación en 3 años | -41.39% |
| Variación en 5 años | -96.25% |
| Variación desde la OPV | -92.19% |
Noticias y actualizaciones recientes
Recent updates
ACB: Rescheduling Tailwinds And Medical Portfolio Expansion Will Shape Balanced Outlook
Analysts have adjusted their CA$ price target on Aurora Cannabis to reflect updated expectations for slightly improved revenue trends, a higher profit margin outlook, and a lower future P/E, supported in part by recent Street research that views partial cannabis rescheduling as extremely favorable for the sector. What's in the News Aurora Cannabis received Plant Breeders' Rights in Canada for two proprietary cultivars, Farm Gas and Driftwood Diesel, giving the company exclusive rights to grow, propagate, and sell products from these varieties across key medical markets.ACB: Partial Rescheduling And Medical Portfolio Shifts Will Shape Balanced Outlook
Analysts have revised their Aurora Cannabis price target to CA$5.00 from CA$5.00, citing updated views on regulatory progress around partial cannabis rescheduling and its potential implications for the company’s risk profile and long term earnings power. Analyst Commentary Recent commentary highlights that partial cannabis rescheduling is viewed as extremely favorable for the sector, but bearish analysts remain cautious on how much of that potential is already reflected in Aurora Cannabis' valuation at the current CA$5.00 price target.ACB: Reset P E Multiple And Equity Issuance Will Shape Balanced Outlook
Analysts have reduced their CA$ price target on Aurora Cannabis by CA$1. This change reflects updated views on profit margins, revenue trends, and a lower assumed future P/E multiple.ACB: Revised P E Assumptions And Policy Signals Will Guide Balanced Outlook
Aurora Cannabis' consensus analyst price target has been reduced by CA$1 as analysts factor in updated views on revenue trends, margin expectations, and a lower assumed future P/E multiple. Analyst Commentary Recent research updates point to a more cautious tone around Aurora Cannabis, as analysts reassess what they are willing to pay for the stock in light of current revenue and margin expectations.ACB: Policy Shifts And Margin Efficiency Will Shape Cautious Yet Balanced Outlook
Aurora Cannabis' consensus analyst price target has been reduced by CA$1, as analysts adjust their models to reflect slightly lower revenue expectations, modestly higher profit margins, and a marginally lower future P/E multiple. Analyst Commentary Recent Street research around Aurora Cannabis reflects a more cautious tone on valuation and execution, even where overall views remain constructive.ACB: Policy Shifts And Margin Execution Will Shape Fairly Balanced Outlook
Narrative update overview The latest analyst update trims the Aurora Cannabis price target by CA$1. This reflects a shift to lower expected profit margins and a higher assumed future P/E multiple, while still leaning on prior bullish initiation as support for the longer-term story.ACB: Policy Shift And Execution Uncertainty Will Shape Balanced Risk Profile
Aurora Cannabis: Narrative Update Analysts reduced their 12-month price target for Aurora Cannabis by CA$1. This reflects updated expectations that now assume slightly softer revenue growth, somewhat higher profit margins, and a lower future P/E multiple.ACB: Mixed Policy And Execution Signals Will Shape Risk Profile Ahead
Analysts have trimmed their fair value target for Aurora Cannabis from C$6.00 to C$5.00. This reflects an updated view that factors in a higher discount rate, revised revenue growth assumptions, improved profit margin expectations, and a lower future P/E multiple after recent Street research, including the latest Canaccord price target cut and an earlier bullish initiation.Aurora Cannabis Inc. (TSE:ACB) Stocks Pounded By 28% But Not Lagging Industry On Growth Or Pricing
Aurora Cannabis Inc. ( TSE:ACB ) shares have retraced a considerable 28% in the last month, reversing a fair amount of...Is Aurora Cannabis (TSE:ACB) Weighed On By Its Debt Load?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Aurora Cannabis Inc. (TSE:ACB) Stocks Shoot Up 27% But Its P/S Still Looks Reasonable
Aurora Cannabis Inc. ( TSE:ACB ) shares have had a really impressive month, gaining 27% after a shaky period...
European And Australian Medical Cannabis Markets Will Unlock Enduring Potential
Despite substantial improvement in net profit margin and a sharply reduced future P/E ratio, the consensus analyst price target for Aurora Cannabis has decreased from CA$8.42 to CA$7.92. What's in the News Aurora Cannabis expects year-over-year net revenue growth in Q2 2026, primarily driven by an 8%–12% increase in its Global Medical Cannabis segment (Corporate Guidance – New/Confirmed, 2025-08-06).Aurora Cannabis Inc. (TSE:ACB) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Aurora Cannabis Inc. ( TSE:ACB ) shares have retraced a considerable 26% in the last month, reversing a fair amount of...Aurora Cannabis' (TSE:ACB) Earnings May Just Be The Starting Point
Investors were underwhelmed by the solid earnings posted by Aurora Cannabis Inc. ( TSE:ACB ) recently. We did some...After Leaping 29% Aurora Cannabis Inc. (TSE:ACB) Shares Are Not Flying Under The Radar
Those holding Aurora Cannabis Inc. ( TSE:ACB ) shares would be relieved that the share price has rebounded 29% in the...
EU GMP And TGA Expertise Will Expand Global Cannabis Reach
Strategic international expansion and regulatory changes in key markets could significantly boost future revenues and medical cannabis margins.Investors Give Aurora Cannabis Inc. (TSE:ACB) Shares A 26% Hiding
Unfortunately for some shareholders, the Aurora Cannabis Inc. ( TSE:ACB ) share price has dived 26% in the last thirty...Aurora Cannabis Inc.'s (TSE:ACB) Share Price Is Still Matching Investor Opinion Despite 29% Slump
Aurora Cannabis Inc. ( TSE:ACB ) shareholders that were waiting for something to happen have been dealt a blow with a...It's Unlikely That Aurora Cannabis Inc.'s (TSE:ACB) CEO Will See A Huge Pay Rise This Year
Key Insights Aurora Cannabis to hold its Annual General Meeting on 9th of August Salary of CA$773.6k is part of CEO...Aurora Cannabis Inc.'s (TSE:ACB) Share Price Is Still Matching Investor Opinion Despite 29% Slump
Aurora Cannabis Inc. ( TSE:ACB ) shares have retraced a considerable 29% in the last month, reversing a fair amount of...Why Aurora Cannabis' (TSE:ACB) Earnings Are Weaker Than They Seem
We didn't see Aurora Cannabis Inc.'s ( TSE:ACB ) stock surge when it reported robust earnings recently. We decided to...Rentabilidad de los accionistas
| ACB | CA Pharmaceuticals | Mercado CA | |
|---|---|---|---|
| 7D | -0.7% | -1.4% | -0.4% |
| 1Y | -24.5% | 59.2% | 31.5% |
Rentabilidad vs. Industria: Los resultados de ACB fueron inferiores a los de la industria Canadian Pharmaceuticals, que obtuvo un rendimiento del 59.2% el año pasado.
Rentabilidad vs. Mercado: ACB obtuvo unos resultados inferiores a los del mercado Canadian, que fueron del 31.5% el año pasado.
Volatilidad de los precios
| ACB volatility | |
|---|---|
| ACB Average Weekly Movement | 7.4% |
| Pharmaceuticals Industry Average Movement | 10.5% |
| Market Average Movement | 9.9% |
| 10% most volatile stocks in CA Market | 17.1% |
| 10% least volatile stocks in CA Market | 3.8% |
Precio estable de las acciones: ACB no ha tenido una volatilidad de precios significativa en los últimos 3 meses en comparación con el mercado Canadian.
Volatilidad a lo largo del tiempo: La volatilidad semanal de ACB (7%) se ha mantenido estable durante el año pasado.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 2013 | 1,028 | Miguel Martin | www.auroramj.com |
Aurora Cannabis Inc., junto con sus filiales, se dedica a la producción, distribución y venta de cannabis y productos derivados en Canadá y a escala internacional. Opera a través de dos segmentos, Canadian Cannabis y Plant Propagation. La empresa ofrece productos de cannabis médicos y de consumo; suministra vegetales propagados y plantas ornamentales; y distribuye y vende productos de cannabidiol (CBD) derivados del cáñamo.
Resumen de fundamentos de Aurora Cannabis Inc.
| Estadísticas fundamentales de ACB | |
|---|---|
| Capitalización bursátil | CA$257.06m |
| Beneficios(TTM) | -CA$58.62m |
| Ingresos (TTM) | CA$320.59m |
¿Está ACB sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de ACB | |
|---|---|
| Ingresos | CA$320.59m |
| Coste de los ingresos | CA$183.94m |
| Beneficio bruto | CA$136.65m |
| Otros gastos | CA$195.27m |
| Beneficios | -CA$58.62m |
Últimos beneficios comunicados
Mar 31, 2026
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -0.95 |
| Margen bruto | 42.62% |
| Margen de beneficio neto | -18.28% |
| Ratio deuda/patrimonio | 0% |
¿Cómo se ha desempeñado ACB a largo plazo?
Ver rendimiento histórico y comparativaAnálisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/06/19 22:14 |
| Precio de las acciones al final del día | 2026/06/19 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2026/03/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también contamos con guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Aurora Cannabis Inc. está cubierta por 15 analistas. 6 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Frederico Yokota Choucair Gomes | ATB Cormark |
| Etienne Ricard | BMO Capital Markets Equity Research |
| Heather Balsky | BofA Global Research |